Evolent Health Inc (EVH) Given Consensus Rating of “Buy” by Brokerages
Evolent Health Inc (NYSE:EVH) has received a consensus rating of “Buy” from the sixteen brokerages that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $25.33.
Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. Wells Fargo reduced their price objective on Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity reduced their price target on Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Citigroup initiated coverage on Evolent Health in a research report on Thursday, January 4th. They set a “buy” rating for the company. Finally, Jefferies Group set a $22.00 price target on Evolent Health and gave the company a “buy” rating in a research report on Tuesday, February 13th.
In other Evolent Health news, Director Unitedhealth Group Inc sold 3,040,000 shares of Evolent Health stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $13.70, for a total value of $41,648,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 8.79% of the stock is owned by insiders.
Shares of EVH stock traded down $0.30 during midday trading on Friday, reaching $13.80. The company’s stock had a trading volume of 338,036 shares, compared to its average volume of 937,023. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.85 and a current ratio of 2.85. The firm has a market capitalization of $1,115.09, a P/E ratio of -14.39 and a beta of 1.08. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50.
TRADEMARK VIOLATION WARNING: “Evolent Health Inc (EVH) Given Consensus Rating of “Buy” by Brokerages” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/evolent-health-inc-evh-given-consensus-rating-of-buy-by-brokerages/1960564.html.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.